TNF PHARMACEUTICALS INC (TNFA) Stock Price, Forecast & Analysis
USA - NASDAQ:TNFA - US62856X2018 - Common Stock
TNFA Key Statistics, Chart & Performance
The current stock price of TNFA is 5.2 USD. In the past month the price decreased by -33.25%. In the past year, price decreased by -96.6%.
TNFA Latest News, Press Relases and Analysis
TNFA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
Related stock screener links
About TNFA
Company Profile
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.
Company Info
TNF PHARMACEUTICALS INC
1185 Avenue Of The Americas, Suite 249
New York City NEW YORK US
Employees: 2
Phone: 18568488698
TNF PHARMACEUTICALS INC / TNFA FAQ
Can you describe the business of TNF PHARMACEUTICALS INC?
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.
What is the current price of TNFA stock?
The current stock price of TNFA is 5.2 USD. The price increased by 48.15% in the last trading session.
What is the dividend status of TNF PHARMACEUTICALS INC?
TNFA does not pay a dividend.
How is the ChartMill rating for TNF PHARMACEUTICALS INC?
TNFA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for TNFA stock?
TNF PHARMACEUTICALS INC (TNFA) currently has 2 employees.
TNFA Technical Analysis
TNFA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |